Skip to main content

Table 2 Paired comparison of clinical parameters between baseline and week 2 in different outcomes and treatment groups

From: On-treatment mortality predictors in chronic hepatitis B patients experiencing severe acute exacerbation: a prospective observational study

  Overall   Survival   Mortality   Telbivudine   Entecavir  
Patient no 21   17   4   9   12  
Time point Baseline Week 2 p Baseline Week 2a p Baseline Week 2a P Baseline Week 2b p Baseline Week 2b p
ALT 1270 (146–2480) 167 (41–485) <0.001 1270 (211–2480) 184 (41–485) <0.001 1197 (146–2247) 112.5 (66–190) 0.068 1523 (211–2480) 184 (80–435) 0.011 870 (146–2247) 133.5 (41–485) 0.002
Bilirubin T 9.2 (2.1–33.1) 6.8 (1.8–43.2) 0.728 7.7 (2.1–16.8) 4.8 (1.8–21.3) 0.309 20.6 (11.9–33.1) 29.1 (17.8–43.2) 0.068 8.6 (2.1–20.4) 8.0 (1.9–25.3) 0.515 10.25 (2.2–33.1) 5.15 (1.8–43.2) 1.000
Creatinine 0.68 (0.39–1.46) 0.94 (0.37–3.79) 0.002 0.71 (0.47–1.34) 1.0 (0.37–1.81) 0.019 0.48 (0.39–1.46) 0.92 (0.72–3.79) 0.068 0.71 (0.47–1.05) 0.90 (0.59–1.49) 0.051 0.63 (0.39–1.46) 1.03 (0.37–3.79) 0.021
eGFR                
MDRD 116 (53–254) 89 (18–241) 0.005 116 (53–183) 77 (37–241) 0.042 194.5 (54–254) 90.5 (18–129) 0.068 116 (73–201) 89 (37–147) 0.044 127 (53–254) 79 (18–241) 0.050
CKD-EPI 111.1 (52.9–156.7) 98.3 (18.9–134.5) 0.003 110.1 (52.9–131.1) 82.9 (36.8–134.5) 0.028 138.2 (59.8–156.7) 101.8 (18.9–126.4) 0.068 112 (77.8–148) 98.3 (40.9–126.4) 0.066 110.6 (5.29–56.7) 86.9 (18.9–134.5) 0.028
INR 1.6 (1.3–3.5) 1.4 (1.0–4.2) 0.066 1.5 (1.3–2.3) 1.3 (1.0–2.8) 0.062 3.3 (2.6–3.5) 2.75 (2.2–4.2) 0.577 1.5 (1.3–3.1) 1.7 (1.1–2.8) 0.440 1.6 (1.4–3.5) 1.35 (1.0–4.2) 0.058
AFP 65.7 (4.1–650.7) 305.5 (6.2–2802) 0.013 49.4 (4.1–477.2) 459.6 (35.4–2802) 0.005 109.5 (27.9–650.7) 36.3 (6.2–66.3) 0.180 27.9 (4.2–238.3) 191.9 (66.3–1462.5) 0.046 162.1 (4.1–650.7) 459.6 (6.2–2802) 0.139
HBV DNA (log10 cps/ml) 8.04 (4.3–9.68) 4.19 (3.07–5.89) <0.001 8.16 (5.22–5.06) 4.2 (3.07–5.89) 0.001 5.06 (4.3–8.2) 3.64 (3.31–3.96) 0.180 8.04 (4.97–9.47) 3.96 (3.07–5.10) 0.018 8.04 (4.30–9.68) 4.20 (3.13–5.89) 0.005
MELD score 20 (13–37) 19 (11–49) 0.283 19 (13–28) 17 (11–32) 0.166 31.5 (26–.7) 30 (26–49) 0.655 19 (14–31) 20 (11–32) 0.674 20 (13–37) 18 (11–49) 0.469
  1. Data shown as median (range); eGFR estimated glomerular filtration rate, MDRD modification of diet in renal disease (mL/min/1.73m2), CKD-EPI Chronic Kidney Disease Epidemiology Collaboration (mL/min/1.73m2), INR international normalized ratio, AFP alpha-fetoprotein, MELD model for end-stage liver disease.
  2. a: comparison of week 2 data between survival and mortality, p values in order were 0.324, 0.003, 0.720, 0.788, 1.000, 0.004, 0.039, 0.160, 0.006.
  3. b: comparison of week 2 data between Telbivudine and Entecavir, p values in order were 0.394, 0.776, 0.776, 0.803, 0.670, 0.642, 1.000, 0.242, 0.915.